Kura Oncology is experiencing a positive shift as it transitions into a commercial-stage company following the FDA approval of its cancer drug, Komzifti, for specific acute myeloid leukemia patients. Analyst Priyanka Grover from JPMorgan initiated coverage with an overweight rating and set a year-end price target of $30, indicating a potential 180% increase from the current share price of $10.71.
The early sales figures for Komzifti show a rise from $2.1 million in late 2025 to $9.1 million in Q2 2026, reflecting strong physician adoption. JPMorgan estimates that expanding Komzifti's use to newly diagnosed patients could lead to peak sales of approximately $1.5 billion.
Additionally, the firm sees promise in Kura's experimental drug, darlifarnib, which could generate $600 million in peak sales, further establishing Kura's presence in the oncology market. As clinical trials advance, JPMorgan believes Kura shares hold significant upside potential, driven by the growing recognition of both Komzifti and darlifarnib in treating cancer